SignalXSignalX

AARD Aardvark Therapeutics, Inc.

Q3 2025 10-Q
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Aardvark Therapeutics, Inc. Overview

Aardvark Therapeutics, Inc. (AARD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Material weakness in internal control over financial reporting identified, may affect accurate or timely financial reporting and investor confidence
  • • Material update: Net loss increased from $11.8M to $40.0M for nine months ended Sept 30, driven by higher R&D and G&A expenses
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$0

Net Income

-$16M

ROE

-13.3%

Total Assets

$133M

Source: XBRL data from Aardvark Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Aardvark Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.